← Back to Home

BioNTech Terminates Colorectal Cancer mRNA Vaccine Trial: Imbalance in Survival Data, No New Safety Signals

Using personalized vaccines after surgery to prevent cancer recurrence continues to face clinical challenges. BioNTech has terminated a Phase 2 study after the monitoring committee concluded that continuing the trial was unlikely to change the efficacy outcome. The magnitude and causes of the survival difference, however, await clarification from the full data.

By SURL BioNews

When cancer DNA remains detectable in the blood after tumor removal, reducing the risk of recurrence presents a challenge for postoperative treatment. BioNTech had hoped to address this gap with a personalized mRNA cancer vaccine, but on August 28, 2026, the company announced that it was terminating its Phase 2 trial in these colorectal cancer patients. An independent data safety monitoring committee found a numerical imbalance in overall survival data between the two patient groups and concluded that continuing the trial was unlikely to change the efficacy outcome.

The study, called BNT122-01, tested autogene cevumeran, jointly developed by BioNTech and Roche subsidiary Genentech. The vaccine is made according to the characteristics of each patient's tumor and is intended to guide the immune system to recognize cancer cells. The study enrolled patients with resected, high-risk stage II or stage III colorectal cancer who tested positive for circulating tumor DNA (ctDNA), a blood marker that can provide evidence that residual cancer cells may remain in the body.

According to CancerNetwork's summary, the randomized, open-label trial originally planned to enroll approximately 327 participants to compare vaccine monotherapy with close observation. At least five neoantigens had to be identified in patients' tumor samples to support personalized manufacturing. The primary endpoint was disease-free survival, meaning the length of time patients remained alive without recurrence; overall survival and safety were secondary endpoints. Reuters also reported that the vaccine was administered after surgery and three months of chemotherapy.

The trial had already crossed its prespecified “futility boundary” in October 2025, meaning that the data available at the time indicated an unfavorable outlook for meeting the efficacy objective. However, the monitoring committee then considered the data immature and the follow-up insufficient to reliably assess the primary endpoint. In the absence of safety concerns, the company therefore continued the study. The latest review prompted the committee to recommend stopping trial treatment and terminating the study.

The meaning of the imbalance in survival data needs to be understood separately from safety signals. BioNTech explicitly stated that the committee had identified no new safety signals related to autogene cevumeran, but its announcement did not provide the number of deaths in either group, the direction of the difference, a hazard ratio, or statistical significance. Reuters quoted analysts speculating that the imbalance could mean there were more deaths in the vaccine group. This is market analysis, rather than trial results disclosed by the company, and it cannot currently establish that the vaccine caused an increase in deaths.

This setback highlights limitations of the strategy of using a personalized vaccine alone in this postoperative patient population. BioNTech noted that the immunosuppressive microenvironment in colorectal cancer presents a treatment challenge. However, this study is not sufficient to explain the specific reasons for the poor efficacy, nor can it directly support an inference that all mRNA cancer vaccines will produce the same results. Cancer type, patient selection, and whether other treatments are combined with the vaccine all affect how broadly the results apply.

The Phase 2 IMcode003 trial of the same vaccine as a postoperative treatment for pancreatic ductal adenocarcinoma is currently unaffected and continues as planned. That study combines the vaccine with immune checkpoint inhibition and chemotherapy. BioNTech said it would further analyze the colorectal cancer trial data and disclose the results at an appropriate time. Until the full data are disclosed, it remains unclear which factors led to this failure and whether adjusting patient selection or treatment combinations could improve outcomes.

References

  1. pharma.economictimes.indiatimes.com
  2. BioNTech SE (SEC-hosted release)
  3. CancerNetwork
  4. Reuters (via WSAU)